103 related articles for article (PubMed ID: 7634172)
1. Chronotherapy of growth factors.
Wood PA
J Infus Chemother; 1995; 5(1):20-3. PubMed ID: 7634172
[TBL] [Abstract][Full Text] [Related]
2. Cancer chronotherapy: a drug delivery challenge.
Hrushesky WJ
Prog Clin Biol Res; 1990; 341A():1-10. PubMed ID: 2145583
[TBL] [Abstract][Full Text] [Related]
3. Chronotherapeutics: the relevance of timing in cancer therapy.
Lévi F
Cancer Causes Control; 2006 May; 17(4):611-21. PubMed ID: 16596317
[TBL] [Abstract][Full Text] [Related]
4. [Chronopharmacology and chronotherapy of cancers].
Lévi F
Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
[TBL] [Abstract][Full Text] [Related]
5. [The circadian-timing system: a determinant of drug activity and a target of anticancer treatments].
Lévi F
Ann Pharm Fr; 2008 Jun; 66(3):175-84. PubMed ID: 18706346
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the chronotherapeutic index in the experimental animal laboratory.
Halberg E; Cornélissen G; Halberg F
In Vivo; 1992; 6(4):371-85. PubMed ID: 1520840
[TBL] [Abstract][Full Text] [Related]
7. Chronotherapy and the molecular clock: Clinical implications in oncology.
Innominato PF; Lévi FA; Bjarnason GA
Adv Drug Deliv Rev; 2010 Jul; 62(9-10):979-1001. PubMed ID: 20600409
[TBL] [Abstract][Full Text] [Related]
8. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
9. Biologic rhythms in hematology.
Haus E
Pathol Biol (Paris); 1996 Sep; 44(7):618-30. PubMed ID: 8977919
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
11. [Chronobiology and cancer].
Lévi F
Pathol Biol (Paris); 1987 Jun; 35(6):960-8. PubMed ID: 3306577
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
13. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate.
Natoli C; Salini V; Irtelli L; Martino MT; Garufi C; Grassadonia A; Fiorentino B; Iacobelli S
Anticancer Res; 1996; 16(3A):1275-9. PubMed ID: 8702250
[TBL] [Abstract][Full Text] [Related]
15. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.
Perillo A; Pierelli L; Battaglia A; Salerno MG; Rutella S; Cortesi E; Fattorossi A; De Rosa L; Ferraù F; Lalle M; Leone G; Mancuso S; Scambia G
Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
17. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice.
Takane H; Ohdo S; Yamada T; Yukawa E; Higuchi S
J Pharmacol Exp Ther; 2000 Aug; 294(2):746-52. PubMed ID: 10900256
[TBL] [Abstract][Full Text] [Related]
18. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
19. Biological perspectives on circadian cancer therapy.
Wood PA; Hrushesky WJ
J Infus Chemother; 1995; 5(4):182-90. PubMed ID: 8934723
[TBL] [Abstract][Full Text] [Related]
20. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
